As of November 6, 2026, NewAmsterdam Pharma Co N.V. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 24, 2026 to August 14, 2026, naming 1 appointment. The latest filing names Robert W. Gunning, appointed (Form 8-K, August 14, 2026).
Who owns NewAmsterdam Pharma Co N.V.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like NewAmsterdam Pharma Co N.V? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Robert W. Gunning · 8-K, 2026-08-14
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-08-14
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-22
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-24
NewAmsterdam Pharma Co N.V. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-24 to 2026-08-14. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as NewAmsterdam Pharma Co N.V. files it.
Also on the record for NewAmsterdam Pharma Co N.V.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10% of the class | 5%+ stakes | Source |
| September 22, 2026 | Stake report, Schedule 13D/A, by Frazier Life Sciences X, L.P. | 8.7% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.8% of the class | 5%+ stakes | Source |
| June 4, 2026 | Stake report, Schedule 13G/A, by Capital World Investors | 10.4% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13D/A, by BCLS II Investco, LP | 1.76% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.6% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by VIKING GLOBAL INVESTORS LP | 3.7% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 5.7% of the class | 5%+ stakes | Source |
| December 4, 2025 | Stake report, Schedule 13D/A, by BCLS II Investco, LP | 4.7% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Capital World Investors | 8.7% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13D/A, by BCLS II Investco, LP | 9.99% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13D/A, by Frazier Life Sciences X, L.P. | 7.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs NewAmsterdam Pharma Co N.V. now and the warning signs.
Free to see. No signup.
Keep reading
More on NewAmsterdam Pharma Co N.V. and the records around it.
NewAmsterdam Pharma Co N.V. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Frazier Life Sciences X, L.P. also filed stake reports on 1 other company: Aspen Neuroscience, Inc. (Nov 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
Watch NewAmsterdam Pharma Co N.V.
Get an email when NewAmsterdam Pharma Co N.V. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NewAmsterdam Pharma Co N.V.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NewAmsterdam Pharma Co N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NewAmsterdam Pharma Co N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-14 | In | 8-K, 2026-08-14 | |||
| 2026-08-14 | Reported | not named in the filing | 8-K/A, 2026-08-14 | ||
| 2026-07-22 | Reported | not named in the filing | 8-K, 2026-07-22 | ||
| 2026-04-24 | Reported | not named in the filing | 8-K, 2026-04-24 |
New leaders reset buying decisions — get the Full Report on NewAmsterdam Pharma Co N.V.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at NewAmsterdam Pharma Co N.V., with the record behind each one.
Find candidates like senior executive at NewAmsterdam Pharma Co N.V.Every change, in the filing's words
Appointed: Robert W. Gunning
(the "Company") appointed Robert W. Gunning, age 55, as its principal accounting officer.
- Mr. Gunning succeeds Louise Kooij, whose departure from the Company effective August 31, 2026, was previously announced, in such capacity.
- Mr. Gunning joined the Company as Vice President, Controller, on August 10, 2026.
- Prior to joining the Company, Mr. Gunning served as Interim Controller and a consultant on other financial and accounting matters to Altimmune, Inc., a biopharmaceutical company, from April 2026 until July 2026.
- From April 2022 until April 2026, Mr. Gunning served as Vice President Finance and Corporate Controller at Y-mAbs Therapeutics, Inc., a biopharmaceutical company, that was acquired by SERB Pharmaceuticals, a global specialty pharmaceutical company.
- From August 2021 until April 2022, he served as Vice President, Controller at Excision Biotherapeutics, Inc., a biotechnology company, and prior to that, he served as Chief Financial Officer (US) at Advanced Accelerator Applications USA, Inc., a pharmaceutical company owned by Novartis.
- Mr. Gunning holds a bachelor of business administration degree from Pace University.
Reported
Also on the Separation Date, Mr. Kling entered into an Advisor Agreement (the "Advisor Agreement") with NewAmsterdam Pharma B.V., a wholly owned subsidiary of the Company, pursuant to which Mr. Kling will provide transition and advisory services related to the Company's PREVAIL clinical trial of obicetrapib and other clinical programs in exchange for a service fee of $50,000 per month plus reimbursable expenses incurred.
- As previously disclosed on July 22, 2026, Douglas Kling resigned as the Company's Chief Operating Officer, effective August 14, 2026 (the "Separation Date"), to be appointed as the chief executive officer of another clinical-stage biotech company.
- On the Separation Date, Mr. Kling entered into a letter agreement (the "Separation Agreement") with the Company's wholly owned subsidiary, NewAmsterdam Pharma Corporation ("NAP Corporation").
- The Separation Agreement contains restrictive covenants, including confidentiality, non-disparagement, and non-solicitation covenants, and a release of claims.
- The Advisor Agreement will terminate on May 14, 2027 unless earlier terminated pursuant to the terms of the agreement.
- The foregoing descriptions of the Separation Agreement and the Advisor Agreement are summaries only and are qualified by reference in their entirety to the Separation Agreement and the Advisor Agreement, respectively, a copy of each of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Reported
(the "Company") that he would resign as the Company's Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company.
- In connection with Mr. Kling's departure, the Company expects to enter into a separation agreement.
- The Company also expects to enter into an advisor agreement with Mr. Kling pursuant to which he will provide transition and advisory services related to the Company's PREVAIL clinical trial of obicetrapib and other clinical programs, subject to mutual agreement of terms.
Reported
(the "Company") and Louise Kooij agreed that her employment as the Company's Chief Accounting Officer would end effective August 31, 2026 (the "Separation Date").
- On April 24, 2026, Ms. Kooij and the Company entered into a separation agreement (the "Separation Agreement").
- Pursuant to the Separation Agreement, following the Separation Date, Ms. Kooij is eligible to receive payment of (i) a lump sum equal to twelve months of her base salary as currently in effect, (ii) a pro-rated 2026 annual cash bonus, which payment is representative of target achievement of Ms. Kooij's annual bonus through the Separation Date; and (iii) any accrued but unused holiday and vacation days as of the Separation Date, in accordance with Dutch law.
- In addition, pursuant to the Separation Agreement, the Company agreed (i) to extend the vesting of Ms. Kooij's outstanding stock options and restricted stock unit ("RSU") awards through January 10, 2027, and (ii) that the exercise period for each vested stock option held by Ms. Kooij will expire on February 10, 2027.
- The Separation Agreement contains restrictive covenants, including confidentiality, non-compete and non-disparagement covenants, and a release of claims.
- The foregoing description of the Separation Agreement is a summary only and is qualified by reference in its entirety to the Separation Agreement, a copy of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
Tools for this story
Each opens in a new tab, filled in for NewAmsterdam Pharma Co N.V.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.